{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:15Z","timestamp":1786994415144,"version":"build-2736575974"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","award":["88887.999347\/2024\\u201300"],"award-info":[{"award-number":["88887.999347\/2024\\u201300"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","award":["88887.892473\/2023\\u201300"],"award-info":[{"award-number":["88887.892473\/2023\\u201300"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"FAPERJ","doi-asserted-by":"publisher","award":["E-26\/204.175\/2024"],"award-info":[{"award-number":["E-26\/204.175\/2024"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"FAPERJ","doi-asserted-by":"publisher","award":["SEI-260003\/009111\/2024"],"award-info":[{"award-number":["SEI-260003\/009111\/2024"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"FAPERJ","doi-asserted-by":"publisher","award":["SEI-260003\/006158\/2024"],"award-info":[{"award-number":["SEI-260003\/006158\/2024"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"FAPERJ","doi-asserted-by":"publisher","award":["SEI-260003\/013218\/2024"],"award-info":[{"award-number":["SEI-260003\/013218\/2024"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.msard.2025.106912","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T23:27:07Z","timestamp":1765063627000},"page":"106912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Influence of FCGR2A (rs1801274) and FCGR3A (rs396991) polymorphisms on natalizumab response on multiple sclerosis"],"prefix":"10.1016","volume":"106","author":[{"given":"Rafaella de C","family":"Cardoso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus D","family":"de Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa A","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara D","family":"Guimenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni K","family":"Pavani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Gouvea","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Fran\u00e7a Alcaraz","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ria Coelho Santa Rita","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin\u00edcius B","family":"Domingues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o G D","family":"Farinhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilla A","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe R","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme C","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soniza V","family":"Alves-Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabr\u00edcia L","family":"Fontes-Dantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106912_bib0022","doi-asserted-by":"crossref","first-page":"349","DOI":"10.54029\/2023afn","article-title":"Integrin alpha-4 gene polymorphism in relation to natalizumab response in multiple sclerosis patients","volume":"28","author":"Ahmed","year":"2023","journal-title":"Neurol. Asia"},{"key":"10.1016\/j.msard.2025.106912_bib0025","doi-asserted-by":"crossref","DOI":"10.1186\/s40893-019-0039-0","article-title":"GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients","volume":"4","author":"Al-Mojel","year":"2019","journal-title":"Mult. Scler. Demyelinating. Disord."},{"key":"10.1016\/j.msard.2025.106912_bib0024","first-page":"586","article-title":"Possible implication of GSTP1 and NQO1 polymorphisms on Natalizumab response in multiple sclerosis","volume":"46","author":"Alexoudi","year":"2016","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.msard.2025.106912_bib0010","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1007\/s00415-022-11169-w","article-title":"Patients with multiple sclerosis: a burden and cost of illness study","volume":"269","author":"Battaglia","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106912_bib0009","doi-asserted-by":"crossref","first-page":"E1810","DOI":"10.1212\/WNL.0000000000200150","article-title":"The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs","volume":"98","author":"Bebo","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106912_bib0016","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1468-1331.2010.03112.x","article-title":"Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis","volume":"18","author":"Belachew","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106912_bib0085","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1084\/jem.190.4.585","article-title":"The major receptor for C-reactive protein on leukocytes is fcgamma receptor II","volume":"190","author":"Bharadwaj","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2025.106912_bib0054","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1067\/mai.2003.1380","article-title":"IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy","volume":"111","author":"Binstadt","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.msard.2025.106912_bib0059","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.msard.2025.106912_bib0047","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human fc\u03b3 receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.msard.2025.106912_bib0104","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.taap.2017.07.011","article-title":"In silico pharmacogenetic approach: the natalizumab case study","volume":"330","author":"Cavaliere","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.msard.2025.106912_bib0099","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jocn.2021.04.024","article-title":"Asymptomatic cerebral cavernous angiomas associated with plasma marker signature","volume":"89","author":"Chehuen Bicalho","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2025.106912_bib0021","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-024-12608-6","article-title":"Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study","author":"Clarelli","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106912_bib0098","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1567202618666210603125630","article-title":"Association of variants in FCGR2A, PTPN2, and GM-CSF with cerebral cavernous malformation: potential biomarkers for a symptomatic disease","volume":"18","author":"da Fontoura Galv\u00e1o","year":"2021","journal-title":"Curr. Neurovasc. Res."},{"key":"10.1016\/j.msard.2025.106912_bib0020","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/1352458517753721","article-title":"Prediction of natalizumab anti-drug antibodies persistency","volume":"25","author":"Deisenhammer","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106912_bib0102","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jneuroim.2016.07.020","article-title":"No association between FCGR2A and FCGR3A polymorphisms in Guillain-Barr\u00e9 Syndrome in a Brazilian population","author":"Dourado","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106912_bib0050","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/art.1780381217","article-title":"Skewed distribution of IGG FC receptor iia (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients","volume":"38","author":"Duits","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2025.106912_bib0077","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/labinvest.3700148","article-title":"Human neutrophils produce interferon gamma upon stimulation by interleukin-12","volume":"84","author":"Ethuin","year":"2004","journal-title":"Lab. Investig."},{"key":"10.1016\/j.msard.2025.106912_bib0012","doi-asserted-by":"crossref","first-page":"545","DOI":"10.12998\/wjcc.v3.i7.545","article-title":"Treatment strategies for multiple sclerosis: when to start, when to change, when to stop?","volume":"3","author":"Gajofatto","year":"2015","journal-title":"World J. Clin. Cases."},{"key":"10.1016\/j.msard.2025.106912_bib0078","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1165\/rcmb.2013-0316OC","article-title":"Mechanisms of interferon-\u03b3 production by neutrophils and its function during streptococcus pneumoniae pneumonia","volume":"52","author":"Gomez","year":"2015","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.msard.2025.106912_bib0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12341","article-title":"Fc\u03b3 receptors: genetic variation, function, and disease","volume":"268","author":"Hargreaves","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.msard.2025.106912_bib0048","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/ki.1997.464","article-title":"Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to fc\u03b3riia alleles","volume":"52","author":"Haseley","year":"1997","journal-title":"Kidney Int."},{"key":"10.1016\/j.msard.2025.106912_bib0055","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2007-01-070656","article-title":"Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc\u03b3RIIIa-158 V\/V and V\/F polymorphism","volume":"110","author":"Hatjiharissi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.msard.2025.106912_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12020316","article-title":"Conjecturing about small-molecule agonists and antagonists of \u03b14\u03b21 integrin: from mechanistic insight to potential therapeutic applications","volume":"12","author":"He","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.msard.2025.106912_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00134","article-title":"Pharmacogenomics of multiple sclerosis: a systematic review","volume":"10","author":"Ho\u010devar","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106912_bib0086","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1159\/000343302","article-title":"C-reactive protein increases BBB permeability: implications for obesity and neuroinfammation","volume":"30","author":"Hsuchou","year":"2012","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.msard.2025.106912_bib0062","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00390","article-title":"Impact of human fc\u03b3r gene polymorphisms on IgG-triggered cytokine release: critical importance of cell assay format","volume":"10","author":"Hussain","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106912_bib0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106912_bib0019","article-title":"Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: a descriptive study of test results","volume":"12","author":"Jenny","year":"2017","journal-title":"PLoS. One"},{"key":"10.1016\/j.msard.2025.106912_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001524","article-title":"Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study","volume":"2","author":"Kastbom","year":"2012","journal-title":"BMJ Open."},{"key":"10.1016\/j.msard.2025.106912_bib0026","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/acn3.50935","article-title":"Impact of fc\u03b3r variants on the response to alemtuzumab in multiple sclerosis","volume":"6","author":"Keller","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106912_bib0043","article-title":"The polygenic nature of Multiple sclerosis: genetic variants, immunological modulation, and environmental connections","volume":"25","author":"Khan","year":"2024","journal-title":"Endocr. Metab. Immune Disord. Drug Targets."},{"key":"10.1016\/j.msard.2025.106912_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208837","article-title":"Burden and cost of multiple sclerosis in Brazil","volume":"14","author":"Kobelt","year":"2019","journal-title":"PLoS. One"},{"key":"10.1016\/j.msard.2025.106912_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2025.1523627","article-title":"The influence of genetic polymorphisms on cytokine profiles in pediatric COVID-19: a pilot study","volume":"13","author":"Kozak","year":"2025","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.msard.2025.106912_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102329","article-title":"The weaker-binding fc \u03b3 receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface","volume":"298","author":"Kremer","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.msard.2025.106912_bib0069","doi-asserted-by":"crossref","unstructured":"Krumbholz M., Meinl I., K\u00fcmpfel T., Hohlfeld R., Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. (2008). 10.1212\/01.wnl.0000327671.91357.96.","DOI":"10.1212\/01.wnl.0000327671.91357.96"},{"key":"10.1016\/j.msard.2025.106912_bib0088","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/STROKEAHA.108.535930","article-title":"Mechanisms of C-reactive protein-induced blood-brain barrier disruption","volume":"40","author":"Kuhlmann","year":"2009","journal-title":"Stroke"},{"issue":"11","key":"10.1016\/j.msard.2025.106912_bib0103","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1046\/j.1537-2995.2000.40111388.x","article-title":"Allelic polymorphisms of human fcgamma receptor IIa and fcgamma receptor IIIb among distinct groups in Brazil","volume":"40","author":"Kuwano","year":"2000","journal-title":"Transfus. (Paris)"},{"key":"10.1016\/j.msard.2025.106912_bib0082","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jneumeth.2014.03.002","article-title":"Interleukin-1\u03b2 induces an inflammatory response and the breakdown of the endothelial cell layer in an improved human THBMEC-based in vitro blood-brain barrier model","author":"Labus","year":"2014","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.msard.2025.106912_bib0013","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-14-103","article-title":"Clinical baseline factors predict response to natalizumab: their usefulness in patient selection","volume":"14","author":"Laroni","year":"2014","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2025.106912_bib0034","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt1068","article-title":"DrugBank 4.0: shedding new light on drug metabolism","volume":"42","author":"Law","year":"2014","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.msard.2025.106912_bib0051","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1182\/blood.V94.12.4220","article-title":"Variant genotypes of the low-affinity fcgamma receptors in two control populations and a review of low-affinity fcgamma receptor polymorphisms in control and disease populations","volume":"94","author":"Lehrnbecher","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.msard.2025.106912_bib0079","author":"Leung"},{"key":"10.1016\/j.msard.2025.106912_bib0027","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2004-02-0651","article-title":"FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia","volume":"105","author":"Lin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.msard.2025.106912_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00001","article-title":"Vitamin D is required for ILC3 derived IL-22 and protection from Citrobacter rodentium infection","volume":"10","author":"Lin","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106912_bib0081","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.01271.2005","article-title":"Immune complexes alter cerebral microvessel permeability: roles of complement and leukocyte adhesion","volume":"291","author":"Lister","year":"2006","journal-title":"Am. J. Physiol. Heart. Circ. Physiol."},{"key":"10.1016\/j.msard.2025.106912_bib0052","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.msard.2025.106912_bib0083","author":"Lozada"},{"key":"10.1016\/j.msard.2025.106912_bib0100","doi-asserted-by":"crossref","DOI":"10.1186\/1753-6561-3-S7-S49","article-title":"The effect of multiple genetic variants in predicting the risk of type 2 diabetes","volume":"3","author":"Lu","year":"2009","journal-title":"BMC Proc."},{"key":"10.1016\/j.msard.2025.106912_bib0094","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.msard.2025.106912_bib0032","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/annrheumdis-2018-214649","article-title":"Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases","volume":"78","author":"Martin","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2025.106912_bib0040","author":"Miller"},{"key":"10.1016\/j.msard.2025.106912_bib0076","article-title":"Understanding Fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools","volume":"10","author":"Mkaddem","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106912_bib0029","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4161\/mabs.2.2.11158","article-title":"Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions","volume":"2","author":"Moore","year":"2010","journal-title":"MAbs."},{"key":"10.1016\/j.msard.2025.106912_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103995","article-title":"Use of natalizumab in persons with multiple sclerosis: 2022 update","volume":"65","author":"Morrow","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106912_bib0087","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/diseases11040132","article-title":"C-Reactive protein: pathophysiology, diagnosis, false test results and a novel diagnostic algorithm for clinicians","volume":"11","author":"Mouliou","year":"2023","journal-title":"Diseases"},{"key":"10.1016\/j.msard.2025.106912_bib0057","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/1529-0131(200004)43:4<735::AID-ANR3>3.0.CO;2-Q","article-title":"Involvement of fcgamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis","volume":"43","author":"Nieto","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2025.106912_bib0067","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ana.20859","article-title":"Natalizumab effects on immune cell responses in multiple sclerosis","volume":"59","author":"Niino","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106912_bib0060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2025.106912_bib0042","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrneurol.2010.91","article-title":"Multiple sclerosis genetics\u2013is the glass half full, or half empty?","volume":"6","author":"Oksenberg","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106912_bib0006","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/14737175.2016.1169924","article-title":"Natalizumab in relapsing-remitting multiple sclerosis","volume":"16","author":"Outteryck","year":"2016","journal-title":"Expert. Rev. NeurOther"},{"key":"10.1016\/j.msard.2025.106912_bib0072","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-2249.1998.00597.x","article-title":"Detection of fcgamma receptors on human endothelial cells stimulated with cytokines tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma)","volume":"112","author":"Pan","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2025.106912_bib0071","first-page":"157","article-title":"Expression of endothelial cell IgG fc receptors and markers on various cultures","volume":"112","author":"Pan","year":"1999","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.msard.2025.106912_bib0096","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.28594","article-title":"Biochemical parameters as prognostic markers in severely ill COVID-19 patients","author":"Pitamberwale","year":"2022","journal-title":"Cureus."},{"key":"10.1016\/j.msard.2025.106912_bib0011","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106912_bib0014","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jns.2012.08.027","article-title":"Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis","volume":"323","author":"Prosperini","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106912_bib0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000302687","article-title":"Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells","volume":"63","author":"Putzki","year":"2010","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.msard.2025.106912_bib0084","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.thromres.2013.12.030","article-title":"The proinflammatory effect of C-reactive protein on human endothelial cells depends on the Fc\u03b3RIIa genotype","volume":"133","author":"Raaz-Schrauder","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.msard.2025.106912_bib0053","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.170.2.481","article-title":"Alternative membrane forms of fc gamma RIII (CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions","volume":"170","author":"Ravetch","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2025.106912_bib0041","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.msard.2025.106912_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104343","article-title":"Comprehensive genetic and functional analyses of fc gamma receptors influence on response to rituximab therapy for autoimmunity","volume":"86","author":"Robinson","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2025.106912_bib0080","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-021-01829-4","article-title":"IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection","volume":"4","author":"Rosa","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.msard.2025.106912_bib0023","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1352458512448106","article-title":"A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation","volume":"19","author":"Rossi","year":"2013","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106912_bib0070","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106912_bib0093","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106912_bib0049","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/infdis\/170.4.854","article-title":"Fca receptor iia (Cd32) heterogeneity In patients with recurrent bacterial Respiratory tract infections","volume":"170","author":"Sanders","year":"1994","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.msard.2025.106912_bib0002","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.cgh.2015.07.020","article-title":"Natalizumab for Crohn\u2019s Disease: down but not out","volume":"13","author":"Scott","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.msard.2025.106912_bib0003","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jneuroim.2011.02.010","article-title":"Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients","volume":"235","author":"Skarica","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106912_bib0091","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02797-8","article-title":"High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4+ T cell arrest on the inflamed BBB under flow in vitro","volume":"20","author":"Soldati","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106912_bib0004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1527-3458.2007.00003.x","article-title":"Pharmacological properties, toxicology and scientific rationale for the use of Natalizumab (Tysabri\u00ae) in inflammatory diseases","volume":"13","author":"St\u00fcve","year":"2007","journal-title":"CNS. Drug Rev."},{"key":"10.1016\/j.msard.2025.106912_bib0068","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"St\u00fcve","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106912_bib0089","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI7817","article-title":"C-reactive protein binding to Fc\u03b3RIIa on human monocytes and neutrophils is allele-specific","volume":"105","author":"Stein","year":"2000","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.msard.2025.106912_bib0061","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41435-018-0038-8","article-title":"Effects of an Fc\u03b3RIIA polymorphism on leukocyte gene expression and cytokine responses to anti-CD3 and anti-CD28 antibodies","volume":"20","author":"Stein","year":"2019","journal-title":"Genes. Immun."},{"key":"10.1016\/j.msard.2025.106912_bib0005","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrd1752","article-title":"Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab","volume":"4","author":"Steinman","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.msard.2025.106912_bib0037","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/labinvest.2013.61","article-title":"Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis","volume":"93","author":"Sun","year":"2013","journal-title":"Lab. Investig."},{"key":"10.1016\/j.msard.2025.106912_bib0101","article-title":"Utility of polygenic scores across diverse diseases in a hospital cohort for predictive modeling","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2025.106912_bib0063","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4674-z","article-title":"Fc\u03b3RIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV","volume":"19","author":"Talathi","year":"2019","journal-title":"BMC. Infect. Dis."},{"key":"10.1016\/j.msard.2025.106912_bib0035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00401-012-0995-3","article-title":"Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction","volume":"124","author":"Teeling","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.msard.2025.106912_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1661502","article-title":"Association of FCGR2A rs1801274 and FCGR3A rs396991 polymorphisms with various autoimmune diseases: a meta-analysis","volume":"16","author":"Thaler","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106912_bib0038","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106912_bib0066","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-019-1593-2","article-title":"Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients","volume":"16","author":"Traub","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106912_bib0092","doi-asserted-by":"crossref","first-page":"E745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial","volume":"95","author":"Van Kempen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106912_bib0097","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.msard.2025.106912_bib0064","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.gim.2022.04.005","article-title":"High-affinity Fc\u03b3RIIIa genetic variants and potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) responses contributing to severe COVID-19","volume":"24","author":"Vietzen","year":"2022","journal-title":"Genet. Med."},{"key":"10.1016\/j.msard.2025.106912_bib0073","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00079","article-title":"Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity","volume":"6","author":"Vogelpoel","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106912_bib0046","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.147.4.1338","article-title":"A single amino acid in the second ig-like domain of the human fc gamma receptor II is critical for human IgG2 binding","volume":"147","author":"Warmerdam","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2025.106912_bib0031","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/ibd.21342","article-title":"Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populations","volume":"16","author":"Weersma","year":"2010","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.msard.2025.106912_bib0095","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-023-03048-6","article-title":"Evidence of questionable research practices in clinical prediction models","volume":"21","author":"White","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.msard.2025.106912_bib0033","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.msard.2025.106912_bib0056","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1172\/JCI119616","article-title":"A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease","volume":"100","author":"Wu","year":"1997","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.msard.2025.106912_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11050335","article-title":"Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis","volume":"11","author":"Zarzuelo Romero","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.msard.2025.106912_bib0090","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/art.10930","article-title":"Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune deposits and fc\u03b3 receptor type IIA alleles","volume":"48","author":"Zuniga","year":"2003","journal-title":"Arthritis Rheum."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:48:29Z","timestamp":1781509709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825006509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":102,"alternative-id":["S2211034825006509"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106912","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of FCGR2A (rs1801274) and FCGR3A (rs396991) polymorphisms on natalizumab response on multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106912"}}